MedPath

Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry

Recruiting
Conditions
Autoimmune Diseases
Autoinflammatory Diseases
Registration Number
NCT06417502
Lead Sponsor
Peking Union Medical College Hospital
Brief Summary

An observational, multi-center, longitudinal registry study for Chinese pediatric patients with rheumatic and immunologic diseases.

Detailed Description

Pediatric rheumatic and immunologic diseases severely impact the health of children and adolescents. Chinese Alliance of Pediatric Rheumatic \& Immunologic Diseases (CAPRID) was founded in 2022 to form a national collaboration for high-quality data-driven multi-center pediatric rheumatology and immunology research in China. The CAPRID Registry is an observational, multi-center, longitudinal registry for Chinese pediatric patients with rheumatic and immunologic diseases to explore the clinical phenotypes, diagnoses, complications, real-world drug safety, therapeutic efficacy, adverse events, critical illness and outcomes of Chinese pediatric patients with rheumatic and immunologic diseases.

Hospital-based databases are established and standardized with Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) for routine data collection. A web-based registry website is established with standardized electronic case report forms to register patients from CAPRID centers. A mobile application is created to allow long-term follow up and patient-reported outcome collection. The data captured in this registry reflects a "real world" situation with no intervention done outside the routine clinical practice. Treatment plans are determined by the investigator.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20000
Inclusion Criteria
  • Age <= 18 years old
  • Diagnosed with rheumatic and immunologic diseases (including diffuse connective tissue diseases, arthritis, vasculitis, inborn errors of immunity)
  • Diagnosed and Treated in China
Exclusion Criteria
  • Disagreement of involving in this study by the patient or his/her family.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of Enrolled Patientsup to 10 years

Total number of patients with pediatric rheumatic and immunologic diseases enrolled in the registry

Secondary Outcome Measures
NameTimeMethod
Physician Global Assessmentup to 10 years

Visual Analog Score measurement of disease activity by physicians. The minimum value is 0 and the maximum is 10.

Proportion of Participants with Clinically Inactive Diseaseup to 10 years

Defined by normal disease activity indexes (if available) and normal inflammatory markers (erythrocyte sedimentation rate and C-reactive protein).

Disease activity indexes include Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) for systemic lupus erythematosus; Juvenile Arthritis Disease Activity Score (JADAS)-27 for juvenile idiopathic arthritis, Pediatric Vasculitis Activity Score (PVAS) for vasculitis; Manual Muscle Testing(MMT)8, Childhood Myositis Assessment Scale (CMAS) for juvenile dermatomyositis, Sjögren's syndrome disease activity index (ESSDAI) for Sjögren's syndrome, Modified Rodnan Skin Score for scleroderma.

Patient or Parent Global Assessmentup to 10 years

Visual Analog Score measurement of disease activity by patient's parent or patient him or her self (above 8 years old). The minimum value is 0 and the maximum is 10.

Childhood Health Assessment Questionnaire (CHAQ)up to 10 years

Composite measure of functional disability, score from 0 (no disability) to 3 (severe disability)

Trial Locations

Locations (9)

Shenzhen Children's Hospital

🇨🇳

Shenzhen, Guangdong, China

The Second Xiangya Hospital of Central South University

🇨🇳

Changsha, Hunan, China

Third Hospital of Peking University

🇨🇳

Beijing, Beijing, China

Beijing Children's Hospital, Capital Medical University

🇨🇳

Beijing, Beijing, China

Peking Union Medical College Hospital

🇨🇳

Beijing, Beijing, China

Chidren's Hospital of Chongqing Medical University

🇨🇳

Chongqing, Chongqing, China

The University of Hong Kong Shenzhen Institute of Research and Innovation (HKU-SIRI)

🇨🇳

Shenzhen, Guangdong, China

Children's Hospital of Nanjing Medical University

🇨🇳

Nanjing, Jiangsu, China

Children's Hospital of Zhejiang University School of Medicine

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath